Literature DB >> 5452502

Origin of thymidine kinase in adenovirus-infected human cell lines.

S Kit, K Nakajima, D R Dubbs.   

Abstract

Human adenovirus type 5 enhances the thymidine kinase activity of KB cells but does not induce the enzyme in kinase-deficient HeLa (BU25) cells. Vaccinia induces thymidine kinase activity in both KB and HeLa (BU25) cells. Human adenovirus types 2, 4, 7, and 12 also fail to induce the enzyme in HeLa (BU25) cells. Vaccinia replicates equally well in the presence or absence of HATG (hypoxanthine-aminopterin-thymidine-glycine) in KB and HeLa (BU25) cells. Adenovirus type 5 replicates in KB and in HeLa (BU25) cells in the absence of HATG, and adenovirus type 5 replicates in kinase-positive KB cells in the presence of HATG. However, replication of adenovirus type 5 is grossly inhibited in HeLa (BU25) cells in the presence of HATG. These results suggest that human adenoviruses do not code for a new virus-specific thymidine kinase.

Entities:  

Mesh:

Substances:

Year:  1970        PMID: 5452502      PMCID: PMC376025     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  24 in total

1.  The immunological specificity of thymidine kinases in cells infected by viruses of the herpes group.

Authors:  A Buchan; D H Watson
Journal:  J Gen Virol       Date:  1969-04       Impact factor: 3.891

2.  Origin of the thymidine kinase induced by polyoma virus in productively infected cells.

Authors:  C Basilico; Y Matsuya; H Green
Journal:  J Virol       Date:  1969-02       Impact factor: 5.103

3.  Infection of thymidine kinase-deficient BHK cells with polyoma virus.

Authors:  J W Littlefield; C Basilico
Journal:  Nature       Date:  1966-07-16       Impact factor: 49.962

4.  Stimulation of DNA synthesis and thymidine kinase activity in human embryonic kidney cells infected by Adenovirus 2 or 12.

Authors:  N Ledinko
Journal:  Cancer Res       Date:  1967-08       Impact factor: 12.701

5.  SV 40-specific thymidine kinase.

Authors:  M Hatanaka; R Dulbecco
Journal:  Proc Natl Acad Sci U S A       Date:  1967-11       Impact factor: 11.205

6.  Enhanced thymidine kinase activity following infection of green monkey kidney cells by simian adenoviruses, simian papovavirus SV40, and an adenovirus-SV40 "hybrid".

Authors:  S Kit; D R Dubbs; R A DeTorres; J L Melnick
Journal:  Virology       Date:  1965-11       Impact factor: 3.616

7.  Enhancement of the thymidine kinase activity of human embryonic kidney cells and newborn hamster kidney cells by infection with human adenovirus types 5 and 12.

Authors:  M Takahashi; S Ueda; T Ogino
Journal:  Virology       Date:  1966-12       Impact factor: 3.616

8.  Thymidine kinase activity in cells abortively and productively infected with human adenoviruses.

Authors:  E Bresnick; F Rapp
Journal:  Virology       Date:  1968-04       Impact factor: 3.616

9.  HeLa cells resistant to bromodeoxyuridine and deficient in thymidine kinase activity.

Authors:  S Kit; D R Dubbs; P M Frearson
Journal:  Int J Cancer       Date:  1966-01       Impact factor: 7.396

10.  Kinetics of nucleic acid synthesis in human embryonic kidney cultures infected with adenovirus 2 or 12: inhibition of cellular deoxyribonucleic acid synthesis.

Authors:  N Ledinko; C K Fong
Journal:  J Virol       Date:  1969-08       Impact factor: 5.103

View more
  3 in total

1.  Thymidine kinase of mouse spleen cells in vivo and in vitro.

Authors:  I Olsen; G Harris
Journal:  Biochem J       Date:  1975-02       Impact factor: 3.857

2.  Identification of group'E' chromosome abnormalities in human cells.

Authors:  K E Vause; J K McDougall
Journal:  J Med Genet       Date:  1973-03       Impact factor: 6.318

3.  Ganciclovir inhibits human adenovirus replication and pathogenicity in permissive immunosuppressed Syrian hamsters.

Authors:  Baoling Ying; Ann E Tollefson; Jacqueline F Spencer; Lata Balakrishnan; Stephen Dewhurst; Cristina Capella; R Mark L Buller; Karoly Toth; William S M Wold
Journal:  Antimicrob Agents Chemother       Date:  2014-09-15       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.